Vasomedical, Inc announced on April 16th that it has formally entered into a joint venture with PSK-Health for a worldwide agreement to sell respectively products in various market segments. The joint venture allows Vasomedical and PSK to market their products worldwide with the excpetion of the USA and China. Under their agreement, PSK is the […]
Read moreFDA Reclassifies ECP Devices
External Counterpulsation Therapy (also called ECP or EECP) has been reclassified as a Class II product by the Food & Drug Administration for severe Angina not amendable to surgery. This comes as big news to the External Counterpulsation Therapy industry as the ECP and EECP devices have been categorized as a Class III device. The […]
Read moreEECP Recieves Class IIa Recomendation in Europe
EECP Recieves Class IIa Recommendation in European Society of Cardiology Guidelines for Management of Stable Coronary Artery Disease EECP (Enhanced External Counterpulsation Therapy) is given a lla Class of Recommendation in the 2013 European Society of Cardiology (ESC) Guidelines on the Management of Stable Coronary Artery Disease (SCAD). The guidelines were released during ESC’s annual […]
Read moreHealthcare Reform EECP News
Vasomedical Introduces Policy Makers Focusing on Healthcare Reform to EECP® Therapy April 16th, 2013 Wall Street Journal (full article) Vasomedical, Inc. a worldwide leader in Enhanced External Counterpulsation Therapy (EECP) devices has recently made an effort to contact a group of Congressmen seasoned in the medical field to introduce EECP Therapy as a treatment option […]
Read moreNEWS FLASH: FDA to Evaluate Use of ECP
FDA Meeting of Circulatory System Device Panel scheduled for December 5th, 2012 to evaluate use of ECP Therapy The Food & Drug Administration is holding a meeting on December 5th, 2012 with the Circulatory System Device Panel to discuss 5 key components related to the use External Counterpulsation Therapy (ECP) Devices in the United States. […]
Read moreECP & EECP Therapy Industry News
EECP Therapy Maintains Class IIb Rating with the new ACC/AHA Guidelines for Stable Ischemic Heart Disease (November 27th, 2012) Summary: The American College of Cardiology Foundation and American Heart Association (ACCF/AHA) Guidelines issues practice Guideline every 10 years for treatment of specific heart disease conditions. The Guidelines for the Diagnosis and Management of Patients With […]
Read more